In addition, differences in AKT activity observed in different ovarian cancer cell lines contribute to the cell-specific sensitivity to pharmacological treatment by rapamycin and, more in general, by mTOR inhibitors[16]. The gene discussed is AKT1; the disease is ovarian cancer.